| Â | PFS | OS |
|---|
| Â | HR (95%CI) | P value | HR (95%CI) | P value |
|---|
TTC
a
| Â | Â | Â | Â |
≤ 33 | 1 (Reference) |  | 1 (Reference) |  |
34–40 | 1.18 (0.91–1.52) | 0.221 | 1.57 (1.10–2.23) | 0.012 |
41–49 | 1.18 (0.90–1.53) | 0.227 | 1.85 (1.31–2.62) | 0.001 |
> 49 | 1.15 (0.87–1.51) | 0.338 | 1.51 (1.03–2.19) | 0.033 |
TTC
b
| 1.003 (0.997–1.009) | 0.333 | 1.009 (1.002–1.017) | 0.011 |
PÂ for trendc | Â | 0.381* | Â | 0.031* |
- Abbreviation: PFS, Progression-free survival; OS, Overall survival; TTC, Time to postoperative adjuvant chemotherapy after the completion of neoadjuvant chemotherapy; HR, Hazard ratio; CI, Confidence interval; *, P value for Ptrend
- a Adjusted for age, type, grade, stage, upper abdominal surgery, bowel resection, lymphadenectomy, residual disease, postoperative complication, cycle of neoadjuvant chemotherapy and TTC (included as a quartile categorical variable)
- b Adjusted for age, type, grade, stage, upper abdominal surgery, bowel resection, lymphadenectomy, residual disease, postoperative complication, cycle of neoadjuvant chemotherapy and TTC (included as a continuous variable)
- c Adjusted for age, type, grade, stage, upper abdominal surgery, bowel resection, lymphadenectomy, residual disease, postoperative complication and cycle of neoadjuvant chemotherapy
